BOSTON, MA--(Marketwired - Apr 9, 2013) - Elsevier

New Post Public Reply Private Reply Replies (0) Message Board

Apr 9, 2013 at 9:30 AM

BOSTON, MA--(Marketwired - Apr 9, 2013) - Elsevier Business Intelligence, the medtech industry's leading provider of strategic partnership and investment conferences, announced today that it will host the 'IN3 Medical Device 360° Boston' investor conference on June 24-26, 2013, at the Hyatt Regency Boston. The Investment in Innovation (IN3) Medical Device 360° Boston conference will feature presentations by more than 30 early-, mid- and late-stage start-up companies that are seeking funding and/or strategic partnership across the spectrum of diagnostic and therapeutic device markets. The conference also will feature an outstanding agenda of panels, networking sessions and meet-and-greets with industry thought leaders discussing the most pressing issues facing the global device industry in 2013 and beyond. Panel topics will include: What the Large-Device Acquirers Want to See in a Start-Up Before Buying; Alternative Financing Strategies for Capital: When and Where to Find Them. In addition, large company/VC meet-and-greets will be held to facilitate interaction between these two influential groups and conference participants. Partnering software will be available to all registered attendees prior to the conference so that one-on-one onsite meetings can be pre-arranged. In addition to all of the customary conference benefits, presenting company CEOs will have the opportunity to be interviewed on camera, at no charge, for a 3-minute exclusive video in which they may discuss their company and technology. These interviews will be featured post-conference at www.in3tv.com, to which a link will be provided to participating companies for their unrestricted use; availability of these video interviews will be broadly promulgated within the medtech industry. All one-on-one interviews with presenting-company CEOs will take place at, and during the IN3 Dublin conference and be organized by medtech PR/IR expert Ronald Trahan, President of Ronald Trahan Associates, Inc. Videotaping will take place on a scheduled basis only, on one day only of the event: Tuesday, June 25, from 1:00-5:30 p.m. EDT. To schedule the free on-camera interviews contact rctrahan@ronaldtrahan.com, or call +1-508-359-4005, x108. This special event will benefit a wide variety of participants in the medical device sector: start-ups seeking investment or strategic partnerships, investment firms, VCs, mid-size and large medical device manufacturers, and service providers. Emerging medtech companies that would like to apply to present in Boston should contact Kayleen Kell at 949-797-7142, or email k.kell@elsevier.com. IN3 Medical Device 360° Boston will be held at the Hyatt Regency Boston. Event co-sponsors to date include Ronald Trahan Associates Inc., Marketwired, Mass Medical Angels, Massachusetts Life Sciences Center, MedMarc, and Life Science Intelligence. Visit www.in3Boston.com for more information. About Elsevier Business Intelligence Elsevier Business Intelligence (EBI), an Elsevier company built on the heritage of F-D-C Reports, Windhover Information and Medtech Insight, is a global information supplier providing business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, databases and reports, EBI places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. EBI (www.elsevierbi.com) has offices in the U.S. in Bridgewater, N.J.; Norwalk, Conn.; Rockville, Md.; and Irvine, Calif. Contact: Ronald Trahan, APR Ronald Trahan Associates Inc.508-359-4005, x108

View More

Investors-Hangout-Stock-Message-Boards-thumbnail-2015.png

test123 kjk

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ascletis Targets Obesity with New FDA Submission

Breaking Ground with Innovative Obesity Treatment In the world of biotech, where breakthroughs are hard-fought and the stakes can seem insurmountable, Ascletis Pharma is swinging for the fences with their latest maneuver. They've submitted an Investigational New Drug application to the U.S. Food and Drug Administration for ASC30_39 FDC—a pioneering fixed-dose combo pill...

CREB Unlocks 8.50% APY Bonds for IRA Investors

CRET Broadens the Path to Fixed-Income Security If you're the type who gets a rash just thinking about stock market jitters, pay attention: Compound Real Estate Bonds (CREB) has cracked the door open a bit wider for your retirement peace of mind. They've teamed up with Equity Trust to offer their rock-solid 8.50% APY bonds through self-directed IRAs. That's right—these...

HanAll F&B Maps Bold U.S. Entry with Strategic Pivot

Diving into Uncharted Waters HanAll F&B is setting its sights on the U.S. market, a move that could be make-or-break for this South Korean food manufacturer. With their recent rebranding from Taebaek Sanchae Naengmyeon Farming Association, they're not just changing names—they're shifting operational gears. The name might sound new, but the gutsy ambition behind it is as...

Hansa Bolsters Financials with SERB Deal, Eyes Growth

Financial Gains and Strategic Shifts Oh, here we go again—another quarterly report from Hansa Biopharma, and this one’s got some meat on its bones. They’ve sparked up their financial engine with a hefty €115 million licensing deal with SERB, which is a real shot in the arm. As any investor worth their salt would see, this isn’t just about piling cash. It's...

Brent Crude's Tumult: Oil Giants Weather Market Shifts

Oil Market Faces Uncertain Waves The energy sector's a rough sea these days, with Brent crude prices yo-yoing close to that $100 mark. If you're looking for clarity, don't hold your breath—the EIA's latest report suggests we’re sticking near this price for the foreseeable future before easing into more palatable waters come late 2027. But we ain't there yet, as U.S....

Viatris Engages Investors at Key Healthcare Conferences

Viatris Steps Into the Limelight Across Conferences Investors, listen up—Viatris Inc. is about to spill some beans at a trio of high-stakes healthcare gatherings. Set to rub elbows with the who's who of the biopharma world, this global healthcare crusader's on a mission. They're lining up to have face time at the UBS Global Biopharma Conference, the Jefferies Global...

MOUZ Triumphs at IEM-Beijing 2026, Powered by AutoFull

A Showdown in Beijing: Esports at Its Peak IEM Beijing 2026 wrapped up on November 8, lighting up the Bloomage Biotech•Biohyalux ECM Arena with some high-octane Counter-Strike 2 matches. In a region that's nothing short of a digital battleground, Team MOUZ clinched the crown. And yeah, they didn't just do it solo; they did it seated in style on AutoFull chairs, the...

Modaxo Bolsters Public Transport Support for UITP 2027

Modaxo Steps Up for UITP Summit Hamburg 2027 Well, Modaxo's back at it again, laying down roots in the public transport sector. Fresh off the press, they've announced they'll be a Platinum Partner for the UITP Summit in Hamburg 2027. That's not just a handshake for the cameras, folks. It's a clear shout-out about where they see themselves in this industry. Living Their...

Nielsen's $1.4B Notes to Fuel Bold DoubleVerify Buy

Reading Between the Financial Lines Nielsen's latest move throws a hefty $1.4 billion worth of senior secured notes into the market, aimed at scooping up DoubleVerify in a play that’s as daring as it is dicey. It's the kind of gamble you discuss with your coffee buddy, sipping something strong enough to wake the dead, and exactly the kind of deal that gets seasoned...

PMET's Lithium-Tantalum Study Ups Stakes in Québec Project

Elevated Ambitions in Québec: PMET's Lithium-Tantalum Leap PMET Resources just handed us an intriguing update on their Shaakichiuwaanaan project up in Québec. They're reshaping the roadmap to crank out both lithium and tantalum more efficiently than a bear on a honeycomb. The revised feasibility study has put to paper numbers that have optimists—and skeptics...